Skip to main content

FDA approves Keytruda as adjuvant treatment for kidney cancer

The cancer immunotherapy drug Keytruda, was approved Thursday by the FDA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.